Metraipolis › archive › dc_e92f25966bf7

Clinical Outcomes of Early Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in East Asian Patients with Acute Ischemic Stroke: A… — Europe PMC PMID:42452629

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42452629
DOI
10.3390/jcm15135169
License (as archived)
solo-consultazione
Archived
2026-10-18T11:50:11.193Z
SHA-256 of the archived text
39ea92af0d3170dfacb4ed24ce380ff8444e8dadfc2d287195f11ee9fafc4d94
Stable URL of this page
https://metraipolis.com/documento/dc_e92f25966bf7

How to cite

Clinical Outcomes of Early Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in East Asian Patients with Acute Ischemic Stroke: A… — Europe PMC PMID:42452629 — Europe PMC (en), https://europepmc.org/article/MED/42452629 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e92f25966bf7 (Metraipolis archive dc_e92f25966bf7, sha256 39ea92af0d3170dfacb4ed24ce380ff8444e8dadfc2d287195f11ee9fafc4d94)
BibTeX
@misc{dce92f25966bf7,
  title = {Clinical Outcomes of Early Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in East Asian Patients with Acute Ischemic Stroke: A… — Europe PMC PMID:42452629},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42452629},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e92f25966bf7; sha256 39ea92af0d3170dfacb4ed24ce380ff8444e8dadfc2d287195f11ee9fafc4d94},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42452629. Agents can read the archived copy with the MCP tool read_document.